Montchoisi and Genolier Clinic, Route du Muids 3, Genolier, 1272, Lausanne, Switzerland.
Faculty of Health and Life Sciences, Coventry University, Priory Street, Coventry, CV1 5FB, UK.
Aging Clin Exp Res. 2021 Apr;33(4):1113-1122. doi: 10.1007/s40520-019-01374-5. Epub 2019 Oct 23.
Current vaccination policy in most high-income countries aims to counteract the decline in cell-mediated immunity to varicella zoster virus that occurs with advancing age or immunosuppression. The aim of this review was to describe the burden of illness associated with herpes zoster (HZ) and post-herpetic neuralgia (PHN) risks and their impact on the social and common life in infected people. The effectiveness/efficacy and cost effectiveness of the immunization strategy will be presented through the review of the literature relevant to the live attenuated HZ vaccine (ZLV) licensed in 2006 and the recombinant HZ vaccine (RZV). The latter has very recently been approved to protect aged people aged ≥ 50 years against HZ morbidity including its complications, and associated health-care costs. Finally, this review also provides data with respect of precautions of using and safety of ZVL and RVZ.
目前，大多数高收入国家的疫苗接种政策旨在对抗因年龄增长或免疫抑制而导致的水痘带状疱疹病毒细胞介导免疫的下降。本综述的目的是描述带状疱疹（HZ）和带状疱疹后神经痛（PHN）相关疾病负担及其对感染者社会和日常生活的影响。通过对 2006 年获得许可的减毒活 HZ 疫苗（ZLV）和重组 HZ 疫苗（RZV）相关文献的综述，介绍免疫接种策略的有效性/功效和成本效益。最近，RZV 被批准用于保护年龄≥50 岁的老年人预防 HZ 发病及其并发症，并降低相关医疗保健成本。最后，本综述还提供了关于 ZVL 和 RVZ 使用注意事项和安全性的数据。
